Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033

Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033 Phase 1 study to evaluate safety and immunogenicity of sarbecovirus (coronavirus) vaccine candidate, OVX033, at ascending dose levels  The trial will enroll 48 participants in France Lyon, France – February 15, 2024 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against …

Osivax Appoints Dr. Nicola Groth as Chief Medical Officer

Osivax  Appoints Dr. Nicola Groth as Chief Medical Officer Lyon, France – January 25, 2024 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment of Dr. Nicola Groth, MD, PhD to its executive committee as Chief Medical Officer. She brings over 25 years of experience …